Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw; Satyajit Rajapurkar; Shane W. O’Brien; Sarah V. Gerhart; Lorna H. Mitchell; Nicholas D. Adams; Nathalie Rioux; Trupti Lingaraj; Scott Ribich; Melissa B. Pappalardi; Niyant Shah; Jenny Laraio; Yan Liu; Michael Butticello; Chris Carpenter; Caretha L. Creasy; Susan Korenchuk; Michael T. McCabe; Charles F. McHugh; Raman P. Nagarajan; Craig D. Wagner; Francesca Zappacosta; Roland S. Annan; N.O. Concha; Roberta Thomas; Timothy K. Hart; J. Joshua Smith; Robert A. Copeland; Mikel P. Moyer; John Campbell; Kim Stickland; James E. Mills; Suzanne Jacques-O’Hagan; Christina J. Allain; Danielle Johnston; Alejandra Raimondi; Margaret Porter Scott; Nigel J. Waters; Kerren K. Swinger; Ann Boriack-Sjodin; Tom Riera; Gideon Shapiro; Richard Chesworth; Rabinder Prinjha; Ryan G. Kruger; Olena Barbash; Helai P. Mohammad

doi:10.1016/j.ccell.2019.05.014

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw(GlaxoSmithKline (United States)), Satyajit Rajapurkar(GlaxoSmithKline (United States)), Shane W. O’Brien(GlaxoSmithKline (United States)), Sarah V. Gerhart(GlaxoSmithKline (United States)), Lorna H. Mitchell(Epizyme (United States)), Nicholas D. Adams(GlaxoSmithKline (United States)), Nathalie Rioux(Epizyme (United States)), Trupti Lingaraj(Epizyme (United States)), Scott Ribich(Epizyme (United States)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Niyant Shah(GlaxoSmithKline (United States)), Jenny Laraio(GlaxoSmithKline (United States)), Yan Liu(GlaxoSmithKline (United States)), Michael Butticello(GlaxoSmithKline (United States)), Chris Carpenter(GlaxoSmithKline (United States)), Caretha L. Creasy(GlaxoSmithKline (United States)), Susan Korenchuk(GlaxoSmithKline (United States)), Michael T. McCabe(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Raman P. Nagarajan(GlaxoSmithKline (United States)), Craig D. Wagner(GlaxoSmithKline (United States)), Francesca Zappacosta(GlaxoSmithKline (United States)), Roland S. Annan(GlaxoSmithKline (United States)), N.O. Concha(GlaxoSmithKline (United States)), Roberta Thomas(GlaxoSmithKline (United States)), Timothy K. Hart(GlaxoSmithKline (United States)), J. Joshua Smith(Epizyme (United States)), Robert A. Copeland(Epizyme (United States)), Mikel P. Moyer(Epizyme (United States)), John Campbell(Epizyme (United States)), Kim Stickland(Epizyme (United States)), James E. Mills(Epizyme (United States)), Suzanne Jacques-O’Hagan(Epizyme (United States)), Christina J. Allain(Epizyme (United States)), Danielle Johnston(Epizyme (United States)), Alejandra Raimondi(Epizyme (United States)), Margaret Porter Scott(Epizyme (United States)), Nigel J. Waters(Epizyme (United States)), Kerren K. Swinger(Epizyme (United States)), Ann Boriack-Sjodin(Epizyme (United States)), Tom Riera(Epizyme (United States)), Gideon Shapiro(Epizyme (United States)), Richard Chesworth(Epizyme (United States)), Rabinder Prinjha(GlaxoSmithKline (United States)), Ryan G. Kruger(GlaxoSmithKline (United States)), Olena Barbash(GlaxoSmithKline (United States)), Helai P. Mohammad(GlaxoSmithKline (United States))

Cancer Cell

June 27, 2019

10.1016/j.ccell.2019.05.014

Cited by 345Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis